Spinal Cord Injury - Pipeline Review, H2 2016

Transcription

1 Spinal Cord Injury - Pipeline Review, H2 2016

2 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury Pipeline Review, H2 2016, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape. Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 7, 23 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.spinal Cord Injury. Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System). 3

4 - The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC8703IDB Number of Pages : 192 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Spinal Cord Injury - Pipeline Review, H Table of ContentsTable of Contents 2List of Tables 5List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Spinal Cord Injury Overview 8Therapeutics Development 9Pipeline Products for Spinal Cord Injury - Overview 9Pipeline Products for Spinal Cord Injury - Comparative Analysis 10Spinal Cord Injury - Therapeutics under Development by Companies 11Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes 14Spinal Cord Injury - Pipeline Products Glance 15Late Stage Products 15Clinical Stage Products 16Early Stage Products 17Spinal Cord Injury - Products under Development by Companies 18Spinal Cord Injury - Products under Investigation by Universities/Institutes 21Spinal Cord Injury - Companies Involved in Therapeutics Development 22AbbVie Inc 22Acorda Therapeutics Inc 23Asterias Biotherapeutics, Inc. 24Asubio Pharma Co Ltd 25Athersys Inc 26BioArctic Neuroscience AB 27BioAxone BioSciences Inc 28Genervon Biopharmaceuticals LLC 29Histocell SL 30Kadimastem Ltd 31Kringle Pharma Inc 32Lpath Inc 33MandalMed Inc 34Mapreg SAS 35Medgenics Inc 36Neuralstem Inc 37Neuronax SAS 38New World Laboratories Inc 39Omeros Corp 40PharmatrophiX, Inc. 41Pharmicell Co Ltd 42Protagenic Therapeutics Inc. 43Q Therapeutics Inc 44Remedy Pharmaceuticals Inc 45RespireRx Pharmaceuticals Inc 46SanBio Inc 47Stemedica Cell Technologies Inc 48TissueGene Inc 49TRB Chemedica International SA 50Tumorend LLC 51Vertex Pharmaceuticals Inc 52Vicore Pharma AB 53Spinal Cord Injury - Therapeutics Assessment 54Assessment by Monotherapy Products 54Assessment by Combination Products 55Assessment by Target 56Assessment by Mechanism of Action 59Assessment by Route of Administration 62Assessment by Molecule Type 64Drug Profiles 66(buspirone + carbidopa + levodopa) - Drug Profile 66ABT Drug Profile 67AP Drug Profile 68APO-1 - Drug Profile 69ASTOPC-1 - Drug Profile 70AX Drug Profile 76BA Drug Profile 77BA Drug Profile 78C-21 - Drug Profile 79Cell Therapy for Spinal Cord Injury - Drug Profile 81Cell Therapy to Activate hnt-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 82Cellgram-SCI - Drug Profile 83CHEC-7 - Drug Profile 84CHEC-9 - Drug Profile 85chondroitinase ABC nanosphere - Drug Profile 86CLR-01 - Drug Profile 87CM Drug Profile 88CX Drug Profile 89Drug for Spinal Cord Injury - Drug Profile 91FAB-117HC - Drug Profile 92Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile 93glyburide - Drug Profile 94GM Drug Profile 97HBN-1 - Drug Profile 98ICCN Drug Profile 99IMS Drug Profile 100IMS Drug Profile 101JM-4 - Drug Profile 102KP-100IT - Drug Profile 103LM11A-31BHS - Drug Profile 105LPA Drug Profile 107Lpathomab - Drug Profile 108MAP Drug Profile 111Neu Drug Profile 112NeuroRelease SCI - Drug Profile 113neurovitas - Drug Profile 114NOVO Drug Profile 115NSI Drug Profile 116NWL-53 - Drug Profile 124NX Drug Profile 125Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile 126PF Drug Profile 127porcine GM1 ganglioside - Drug Profile 137PT Drug Profile 138Q-Cells - Drug Profile 139Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile 141Recombinant Protein to Antagonize EPHA4 for ALS, Acute Spinal Cord Injury and Ischemia Reperfusion Injury - Drug Profile 142SB Drug Profile 143SB Drug Profile 144SC Drug Profile 148Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 149Small Molecules for Spinal Cord Injury - Drug Profile 150Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile 151Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 152Stem Cell Therapy for CNS Disorders - Drug Profile 153Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile 154Stem Cell Therapy for Spinal Cord Injury - Drug Profile 156Stem Cell Therapy for Spinal Cord Injury - Drug Profile 157Stem Cell Therapy for Spinal Cord Injury - Drug Profile 158SUN Drug Profile 159Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile 160Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile 161TG-N - Drug Profile 162UH Drug Profile 163UH Drug Profile 164VX Drug Profile 165Spinal Cord Injury - Dormant Projects 168Spinal Cord Injury - Discontinued Products 174Spinal Cord Injury - Product Development Milestones 175Featured News & Press Releases 175Appendix 186Methodology 186Coverage 186Secondary Research 186Primary Research 186Expert Panel Validation 186Contact Us 186Disclaimer 187 6

7 How to Buy... Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 7